Triflusal

Triflusal
Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	B01AC18 (WHO) ;
Identifiers
	IUPAC name 2-acetyloxy-4-(trifluoromethyl)benzoic acid;
PubChem CID	9458;
UNII	1Z0YFI05OO;
ChEMBL	ChEMBL1332032 ;
CompTox Dashboard (EPA)	DTXSID8045305 ;
ECHA InfoCard	100.005.726
Chemical and physical data
Formula	C10H7F3O4
Molar mass	248.155 g/mol g·mol−1
	(what is this?) (verify)

Triflusal is a platelet aggregation inhibitor that was discovered and developed in the Uriach Laboratories, and commercialised in Spain since 1981. Currently, it is available in 25 countries in Europe, Asia, Africa and America. It is a drug of the salicylate family but it is not a derivative of acetylsalicylic acid (ASA). Trade names include Disgren, Grendis, Aflen and Triflux ^[1]

Mechanism of action

Triflusal is a selective platelet antiaggregant through;

blocks cyclooxygenase inhibiting thromboxane A2, preventing aggregation
preserves vascular prostacyclin, thus promoting anti-aggregant effect
blocks phosphodiesterase thereby increasing cAMP concentration, thereby promoting anti-aggregant effect due to inhibition of calcium mobilization

Indication

Triflusal is indicated for;

Prevention of cardiovascular events such as stroke
Acute treatment of cerebral infarction, myocardial infarction
Thromboprophylaxis due to atrial fibrillation

References

^ Murdoch D, et al. Triflusal: a review of its use in cerebral infarction and myocardial infarction, and as thromboprophylaxis in atrial fibrillation.Drugs 2006; 66(5):671-92

This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it.

[1] Murdoch D, et al. Triflusal: a review of its use in cerebral infarction and myocardial infarction, and as thromboprophylaxis in atrial fibrillation.Drugs 2006; 66(5):671-92

[1]